Jason McCarthy, an analyst from Maxim Group, reiterated the Buy rating on Capricor Therapeutics. The associated price target remains the same with $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors related to Capricor Therapeutics’ ongoing developments and future prospects. Despite the recent complete response letter (CRL) from the FDA regarding the Deramiocel BLA for treating Duchenne muscular dystrophy cardiomyopathy, McCarthy remains optimistic about the company’s potential. The upcoming Type A meeting with the FDA is crucial, as it will address the protocol amendment for the Phase 3 HOPE-3 trial, which aims to use left ventricular ejection fraction (LVEF) as the primary endpoint.
Capricor’s strategic move to revert to LVEF as the primary measure aligns with their original plan and could enhance their chances for approval. The trial is fully enrolled, and data is expected soon, which could lead to a BLA resubmission. Furthermore, the company’s financial position, with a cash runway extending into the fourth quarter of 2026, provides a solid foundation for continued operations and development. These factors collectively support McCarthy’s confidence in Capricor’s ability to navigate regulatory challenges and advance their therapeutic offerings, justifying the Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Capricor Therapeutics, and OS Therapies Incorporated. According to TipRanks, McCarthy has an average return of -21.3% and a 26.76% success rate on recommended stocks.
In another report released yesterday, Roth MKM also reiterated a Buy rating on the stock with a $12.00 price target.